Product Information
OLOPATADINE HCL 0.1% EYE DROP is a generic product labeled by SOLA Pharmaceuticals LLC, priced at $1.2737 per ML under NDC 70512052005. Its NADAC has been published 219 times since Jul 27, 2022.
FDA first approved this application on Dec 7, 2015.
Strength
1 mg/mL
Manufacturer
SOLA Pharmaceuticals LLCNDC
70512052005
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
OLOPATADINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203152FDA Approved
12/7/2015
On Market Since
7/5/2022
Pharmacological Classes
Price Statistics
The NADAC for OLOPATADINE HCL 0.1% EYE DROP has been published 219 times since Jul 27, 2022, and over the history we have for it it has declined 12.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2737 per ML |
|---|---|
| All-time high | $1.7041 (Oct 12, 2022) |
| All-time low | $1.0948 (Nov 20, 2024) |
| 52-week high | $1.2895 |
| 52-week low | $1.2029 |
| Median price | $1.3243 |
| Average price | $1.3476 |
| Largest weekly change | -18.3% (Oct 19, 2022) |
| Weeks tracked | 219 |
| Tracking since | Jul 27, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Olopatadine Hcl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SOLA Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Olopatadine Hcl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLOPATADINE HCL 0.1% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for OLOPATADINE HCL 0.1% EYE DROP, manufactured by SOLA Pharmaceuticals LLC, is $1.2737 per ML (NDC 70512052005), effective Sep 30, 2026.
How has the price of OLOPATADINE HCL 0.1% EYE DROP changed over time?
Over the history we have for it, the NADAC for OLOPATADINE HCL 0.1% EYE DROP has declined 12.4%. It has been tracked across 219 weekly CMS publications since Jul 27, 2022.
What are the highest and lowest recorded NADAC prices for OLOPATADINE HCL 0.1% EYE DROP?
Since Jul 27, 2022, the NADAC for OLOPATADINE HCL 0.1% EYE DROP has ranged from a low of $1.0948 (Nov 20, 2024) to a high of $1.7041 (Oct 12, 2022), with a median of $1.3243 per ML.
Are there cheaper alternatives to OLOPATADINE HCL 0.1% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of OLOPATADINE HCL 0.1% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLOPATADINE HCL 0.1% EYE DROP?
OLOPATADINE HCL 0.1% EYE DROP (NDC 70512052005) is labeled by SOLA Pharmaceuticals LLC, and CMS classifies it as a generic product.